



Perinatal-Related Pathology

Guest Editors:

Prof. Dr. Agnieszka Kordek

Department of Neonatology,
Medical University in Szczecin,
Poland, Poland

Dr. Andrzej Torbé

Department of Obstetrics and
Gynecology, Pomeranian Medical
University, Szczecin, Poland

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

An increasing amount of data indicate that the majority of cases of the so-called great obstetrics syndrome are caused by dysfunction of the placenta, which is caused by its impaired development or too-early functional impairment.

Pregnant women with clinical symptoms of placental insufficiency are still doomed to iatrogenic premature termination of pregnancy, and the severity of the pathology is correlated with perinatal outcomes. Therefore, it is worth looking for genetic, biochemical, and biophysical methods that can be used to monitor the course of the disease.

A relationship is sought between the type of bacteria inhabiting the gastrointestinal tract of women and the occurrence of obesity, gestational diabetes, or premature birth, as well as hypoxia and intrauterine infection. Other metabolomes, such as maternal and newborn urine, amniotic fluid, human breast milk, and meconium of the newborn, are also tested. In research on the microbiome in the newborn, the relationship with civilization diseases, infections, and eating disorders is sought. Is it possible to get closer to personalized medicine by using metabolomics?





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI